Membranous Nephropathy Patient-Focused Drug Development Meeting 2021 The 2021 EL-PFDD Meeting on MN was a huge success! View the Recorded Meeting View the Voice of Patient Report View Meeting Transcript What are EL-PFDD meetings? Externally led patient-focused drug development (EL-PFDD) meetings bring together patients and care partners, US Food and Drug Administration (FDA) representatives, pharmaceutical companies, and doctors who are experts in the particular disease. The goal is to hear from patients who have the disease, in order for the FDA and pharmaceutical companies to understand the patient experience. The EL-PFDD meeting on Membranous Nephropathy The National Kidney Foundation and NephCure Kidney International conducted an EL-PFDD meeting on MN to inform the FDA about the patient perspective of living with this disease. Understanding the patient perspective may help the FDA make informed decisions regarding approvals of potential treatments for MN. Voice of the Patient After the meeting, a report titled “Voice of the Patient” is sent to the FDA. This will be a reference for future decisions about potential medicines for MN. The report will be available to the public soon.